Roche (RHHBY), a leading biotechnology company, has announced its financial outlook for the upcoming fiscal year, projecting a notable increase in both group sales and earnings. The company anticipates a rise in group sales within the mid single-digit percentage range, calculated at constant exchange rates (CER).
In addition to the promising sales forecast, Roche has set a target for its core earnings per share to grow at a high single-digit rate, also evaluated at CER. This optimistic outlook underscores Roche's confidence in its strategic initiatives and market performance.
Furthermore, Roche intends to enhance shareholder value by increasing its dividend, which will be paid in Swiss francs. This move reflects the company's commitment to rewarding its investors while maintaining a strong financial foundation.
